Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 132, Issue -, Pages 294-309Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2017.03.062
Keywords
Alzheimer's disease; Selective butyrylcholinesterase inhibitors
Categories
Funding
- National Natural Science Foundation of China [81402851, 81573281]
- Natural Science Foundation of Jiangsu Province [BK20140957]
- Fundamental Research Funds for the Central Universities [2015ZD009]
- Jiangsu Higher Education Institutions [TAPP-PPZY2015A070]
- Jiangsu Higher Education Institutions (PAPD)
Ask authors/readers for more resources
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders with notable factor of dysfunction in cholinergic system. Low ACh level can be observed in the pathogenesis of AD. Several AChE inhibitors have already been used for clinical treatments. However, other than normal conditions, ACh is mostly hydrolyzed by BuChE in progressed AD. Account for an increased level of BuChE and decreased level of AChE in the late stage of AD, development of selective BuChE inhibitor is of vital importance. Up till now, compounds with various scaffolds have been discovered to selectively inhibit BuChE. Different effective anti-BuChE molecules are concluded in this review. (C) 2017 Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available